(Q73599538)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

main subject

phase II clinical trial

1 reference

1 reference

M Packer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

English

0 references

publication date

1 April 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

published in

American Heart Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

S202-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

The placebo effect in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Prevention and reversal of nitrate tolerance in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Decreased Lymphocyte Beta-Adrenergic-Receptor Density in Patients with Heart Failure and Tolerance to the Beta-Adrenergic Agonist Pirbuterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Can drug effects on mortality in heart failure be predicted by any surrogate measure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Role of surrogate end points in the evaluation of drugs for heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Surrogate end points in clinical trials: are we being misled?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990074-7

10.1016/S0002-8703(00)90074-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10740133%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference